Treatments for all cancers, including prostate cancer, have improved over the last ten years. As treatments improve, we have created a growing population of cancer survivors. Neither our hospitals, doctors nor our society has acknowledged this exploding population. We have failed to provide any support system for these survivors, their caregivers or their families. Left [...]
Published in today’s Newsday, the daily newspaper from Long Island, N.Y., was a moving tribute to Lauren Terrazzano. Lauren was a Newsday reporter who, along with articles about the treatment of the elderly and foster children, chronicled her personal life and battle against recurrent lung cancer. Lauren died at Sloane Kettering Hospital last Tuesday night. [...]
There is still time to join us on a sign on action letter to the FDA regarding it’s judgement to delay access to the prostate cancer treatment, Provenge, at www.malecare.com With more new drugs set for FDA consideration this summer, a strong showing of Prostate Cancer patients is vital. Please take a look and if [...]
Prostate cancer is the second leading cause of cancer related deaths among men in the U.S. and many Western countries. African-American men have had higher incidence and at least double the mortality rates compared to men of other racial and ethnic groups. Although early diagnosis of prostate cancer has improved significantly in recent years, there [...]
Spectrum Pharmaceuticals announces that the FDA's Oncology Drug Advisory Committee (ODAC) will review their very promising investigational drug Satraplatin for the Treatment of Hormone Refractory Prostate Cancer. The hearing will be held on July 24, 2007. This is very exciting, especially in light of the FDA’s surprising failure to approve Provenge. A quick review of [...]